View printer-friendly version |
Charles River Laboratories Expands Services for Early Discovery Screening
Addition of high-throughput technologies and expanded pharmacokinetic services enhances existing support for small molecule drug discovery
Early screening provides important insight into a compound’s underlying biology, and streamlined HT-ADME and PK technologies are essential components to identifying promising candidates early in the drug discovery process.
Addition of Apricot Designs’ ADDA System
The ADDA system is a high-speed autosampler designed for drug discovery that provides ADME discovery scientists with a fast sample delivery platform for liquid chromatography/mass spectrometry (LC/MS). Automated permeability, metabolic stability, and protein binding screening assays can be rapidly turned around with the ADDA system and a single mass spectrometer system, saving critical time in the drug discovery process.
Expansion of Pharmacokinetic Capabilities
In both
Therapeutic-area-agnostic PK services support drug discovery efforts from the initial PK screening of compounds and lead optimization to late-stage candidate nomination and Investigational New Drug-enabling studies.
Approved Quotes
- “In early discovery research, screening is an essential component of any successful program. With access to industry-leading technologies, we’re able to provide our clients strategic guidance, ultimately working toward accelerating their programs.” –Birgit Girshick, Corporate Executive Vice President, Discovery and Safety Assessment, Charles River
- “The early discovery industry is seeing a marked shift towards a better understanding of the underlying biology of candidate compounds. Both HT-ADME and PK technologies are critical to that understanding, and to developing more successful candidates in early discovery.” –Ian Waddell, PhD Executive Director, Biology, Charles River
-
“The ADDA system, Apricot Designs’ dual arm autosampler was designed
with early discovery scientists in mind. It enables seamless
integration with LC/MS systems, accelerating the laboratory research
process and yielding the best results.” –Felix H. Yiu, Founder and
CEO,
Apricot Designs, Inc.
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180501005239/en/
Source:
Investor Contact:
Susan E. Hardy, 781-222-6190
Corporate
Vice President, Investor Relations
susan.hardy@crl.com
or
Media
Contact:
Amy Cianciaruso, 781-222-6168
Corporate Vice
President, Public Relations
amy.cianciaruso@crl.com